Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
来源期刊:Drug SafetyDOI:10.1007/s40264-018-0778-4
Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00800-x
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
来源期刊:Drug SafetyDOI:10.1007/s40264-018-00791-1
Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case–Control Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00837-y
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00834-1
Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00836-z
Development and First Use of the Patient’s Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00877-4
Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00852-z
Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00798-2
Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00847-w
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00867-6
Correction to: A Machine-Learning Algorithm to Optimise Automated Adverse Drug Reaction Detection from Clinical Coding
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00820-7
Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00882-7
The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine–Naloxone Tablets
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00883-6
Correction to: Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00802-9
Fatal Toxicity Indices for Medicine-Related Deaths in New Zealand, 2008–2013
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00885-4
Medical Devices: Classification and Analysis of Faults Leading to Harms
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00879-2
Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00844-z
The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00818-1
The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00892-5
Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00803-8